Business Context and Reporting Period
Company: Briacell Therapeutics Corp. (BCTX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 22, 2024
Reporting Period: The filing addresses a specific event occurring on August 22, 2024, regarding the Company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a notice of a listing deficiency and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Listing Deficiency: The Company received a deficiency letter from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of its common shares has been below the minimum $1.00 per share required under Nasdaq Listing Rule 5550(a)(2).
- Current Trading Status: The deficiency letter has no immediate effect on trading. Shares continue to trade on Nasdaq under the symbol "BCTX" and on the Toronto Stock Exchange (TSX) under the symbol "BCT".
- Compliance Timeline: The Company has been granted 180 calendar days, until February 18, 2025, to regain compliance.
Guidance, Outlook, and Risks
- Compliance Path: To regain compliance, the bid price must close at $1.00 or more for a minimum of 10 consecutive business days before February 18, 2025.
- Secondary Compliance Period: If the Company fails to regain compliance by the initial deadline, it may be afforded a second 180-day period. Qualification requires meeting the market value of publicly held shares and other initial listing standards (excluding the bid price requirement) and providing written notice of intent to cure, potentially via a reverse stock split.
- Delisting Risk: If the Company fails to regain compliance by February 18, 2025, and is not eligible for or fails to utilize the second compliance period, Nasdaq will notify the Company that its shares are subject to delisting.
- Appeal Process: The Company may appeal a delisting determination to a hearings panel, though there is no assurance of success.
- Management Commentary: The Company intends to monitor the closing bid price and may consider available options to regain compliance. There is no assurance that compliance will be achieved.
Investor Verification Checklist
- Verify the current closing bid price of BCTX shares relative to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes intended to cure the deficiency.
- Confirm the continued independent listing status on the Toronto Stock Exchange (TSX).
- Track the Company's progress toward the February 18, 2025, compliance deadline.